臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

	English \| 正體中文 \| 简体中文 \| 总笔数 :0
	造访人次 : 51060122 在线人数 : 1159 教育部委托研究计画计画执行:国立台湾大学图书馆

搜寻范围

进阶搜寻

登入

管理

臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

关于TAIR
	计画说明

浏览
	典藏机构
	作者
	题名
	日期
	统计图表
	机构即时统计
	学术趋势

消息
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

著作权
	出版社及期刊政策查询
	TAIR著作权会议记录

相关连结
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"thress k s"的相关文件

回到依作者浏览
依题名排序	依日期排序

显示项目 16-25 / 38 (共4页)
<< < 1 2 3 4 > >>
每页显示[10|25|50]项目

机构	日期	题名	作者
臺大學術典藏	2020-05-26T09:26:44Z	Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity	Box M; Johnström P; Varnäs K; Malmquist J; Thress K.S; Jänne P.A; Cross D.; Cross D.;J?nne P.A;Thress K.S;Malmquist J;Varn?s K;Johnstr?m P;Box M;Grist M;Hickey M;Jordan A;Pickup K;Cantarini M;Chih-Hsin Yang;Kim D.-W;Yang Z;Yates J.W.T;Ballard P; Ballard P; Yates J.W.T; Yang Z; Kim D.-W; CHIH-HSIN YANG; Cantarini M; Pickup K; Jordan A; Hickey M; Grist M
臺大學術典藏	2020-05-26T09:26:44Z	Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity	Box M; Johnström P; Varnäs K; Malmquist J; Thress K.S; Jänne P.A; Cross D.; Cross D.;J?nne P.A;Thress K.S;Malmquist J;Varn?s K;Johnstr?m P;Box M;Grist M;Hickey M;Jordan A;Pickup K;Cantarini M;Chih-Hsin Yang;Kim D.-W;Yang Z;Yates J.W.T;Ballard P; Ballard P; Yates J.W.T; Yang Z; Kim D.-W; CHIH-HSIN YANG; Cantarini M; Pickup K; Jordan A; Hickey M; Grist M
臺大學術典藏	2020-05-26T09:26:44Z	Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer	J?nne P.A.;Barrett J.C;Chih-Hsin Yang;Cantarini M;Paweletz C.P;Lawrance R;Alden R.S;Thress K.S;Oxnard G.R; Oxnard G.R; Thress K.S; Alden R.S; Lawrance R; Paweletz C.P; Cantarini M; CHIH-HSIN YANG; Barrett J.C; Jänne P.A.
臺大學術典藏	2020-05-26T09:26:44Z	Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer	J?nne P.A.;Barrett J.C;Chih-Hsin Yang;Cantarini M;Paweletz C.P;Lawrance R;Alden R.S;Thress K.S;Oxnard G.R; Oxnard G.R; Thress K.S; Alden R.S; Lawrance R; Paweletz C.P; Cantarini M; CHIH-HSIN YANG; Barrett J.C; Jänne P.A.
臺大學術典藏	2020-05-26T09:26:37Z	EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib	Shepherd F.A.;Cantarini M;Patel S;Dearden S;Weston S;Hodge R;Yu K;Thress K.S;J?nne P.A;Chih-Hsin Yang;Jenkins S; Jenkins S; Chih-Hsin CHIH-HSIN YANG; Jänne P.A; Thress K.S; Yu K; Hodge R; Weston S; Dearden S; Patel S; Cantarini M; Shepherd F.A.
臺大學術典藏	2020-05-26T09:26:37Z	EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib	Shepherd F.A.;Cantarini M;Patel S;Dearden S;Weston S;Hodge R;Yu K;Thress K.S;J?nne P.A;Chih-Hsin Yang;Jenkins S; Jenkins S; Chih-Hsin CHIH-HSIN YANG; Jänne P.A; Thress K.S; Yu K; Hodge R; Weston S; Dearden S; Patel S; Cantarini M; Shepherd F.A.
臺大學術典藏	2020-05-26T09:26:35Z	Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial	Thress K.S;Jacobs V;Angell H.K;Chih-Hsin Yang;Sequist L.V;Blackhall F;Su W.-C;Schuler M;Wolf J;Gold K.A;Cantarini M;Barrett J.C;J?nne P.A.; Thress K.S; Jacobs V; Angell H.K; CHIH-HSIN YANG; Sequist L.V; Blackhall F; Su W.-C; Schuler M; Wolf J; Gold K.A; Cantarini M; Barrett J.C; Jänne P.A.
臺大學術典藏	2020-05-26T09:26:35Z	Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial	Thress K.S;Jacobs V;Angell H.K;Chih-Hsin Yang;Sequist L.V;Blackhall F;Su W.-C;Schuler M;Wolf J;Gold K.A;Cantarini M;Barrett J.C;J?nne P.A.; Thress K.S; Jacobs V; Angell H.K; CHIH-HSIN YANG; Sequist L.V; Blackhall F; Su W.-C; Schuler M; Wolf J; Gold K.A; Cantarini M; Barrett J.C; Jänne P.A.
臺大學術典藏	2020-05-26T09:26:34Z	Gefitinib plus chemotherapy versus chemotherapy in epidermal growth factor receptor mutation-positive non-small-cell lung cancer resistant to first-line gefitinib (IMPRESS): Overall survival and biomarker analyses	Soria J.-C.;Thress K.S;Haddad V;Rukazenkov Y;Shi X;Ponce S;Atagi S;Lu Y;Chih-Hsin Yang;Wang J;Ahn M.-J;Yang J.-J;Nakagawa K;Wu Y.-L;Kim S.-W;Mok T.S.K; Mok T.S.K; Kim S.-W; Wu Y.-L; Nakagawa K; Yang J.-J; Ahn M.-J; Wang J; CHIH-HSIN YANG; Lu Y; Atagi S; Ponce S; Shi X; Rukazenkov Y; Haddad V; Thress K.S; Soria J.-C.
臺大學術典藏	2020-05-26T09:26:34Z	Gefitinib plus chemotherapy versus chemotherapy in epidermal growth factor receptor mutation-positive non-small-cell lung cancer resistant to first-line gefitinib (IMPRESS): Overall survival and biomarker analyses	Soria J.-C.;Thress K.S;Haddad V;Rukazenkov Y;Shi X;Ponce S;Atagi S;Lu Y;Chih-Hsin Yang;Wang J;Ahn M.-J;Yang J.-J;Nakagawa K;Wu Y.-L;Kim S.-W;Mok T.S.K; Mok T.S.K; Kim S.-W; Wu Y.-L; Nakagawa K; Yang J.-J; Ahn M.-J; Wang J; CHIH-HSIN YANG; Lu Y; Atagi S; Ponce S; Shi X; Rukazenkov Y; Haddad V; Thress K.S; Soria J.-C.

显示项目 16-25 / 38 (共4页)
<< < 1 2 3 4 > >>
每页显示[10|25|50]项目